Gubra AS (FRA:PI3) Cash Flow from Others: €-59.59 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PI3 Gubra AS FRA:PI3
76 GF Score
Price €41.06
GF Value €26.59
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Gubra AS Cash Flow from Others?

Gubra AS FRA:PI3 +4.75% 76 Cash Flow from Others is €-59.59 Mil as of Jun. 2026. GuruFocus rates FRA:PI3 with a GF Score™ of 76/100 and a GF Value™ of €26.59 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Gubra AS's cash flow from others for the six months ended in Jun. 2026 was €0.26 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Jun. 2026 was €-59.59 Mil.

Gubra AS Cash Flow from Others Related Terms

Gubra AS Cash Flow from Others Historical Data

* Premium members only.

The historical data trend for Gubra AS's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gubra AS Cash Flow from Others Chart

Gubra AS Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow from Others
Get a 7-Day Free Trial 0.16 -4.02 -1.24 0.67 -0.34

Gubra AS Semi-Annual Data
Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Cash Flow from Others Get a 7-Day Free Trial 1.35 1.54 62.61 -59.84 0.26
FRA:PI3
76GF Score
Gubra AS FRA:PI3
Cash Flow from Others is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gubra AS Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-59.59 Mil.

Frequently Asked Questions Learn more about Cash Flow from Others →
What does a Cash Flow from Others of €-59.59 Mil mean?
Gubra AS (FRA:PI3) has a Cash Flow from Others of €-59.59 Mil as of Jun. 2026. Cash Flow from Others is the amount of cash earned or paid from other, nonstandard operations. View historical data for Gubra AS and its competitors.
Is Gubra AS's Cash Flow from Others too high?
Gubra AS's current Cash Flow from Others is €-59.59 Mil. Overall, Gubra AS has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gubra AS's Cash Flow from Others compare to VRTX and REGN?
Gubra AS's Cash Flow from Others of €-59.59 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Others for a Biotechnology company?
A good Cash Flow from Others depends on the Biotechnology industry context. However, Cash Flow from Others should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Others mean?
A high Cash Flow from Others can signal that a stock is expensive relative to its fundamentals. Cash Flow from Others is the amount of cash earned or paid from other, nonstandard operations. View historical data for Gubra AS and its competitors. Gubra AS's current Cash Flow from Others is €-59.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gubra AS stock overvalued right now?
Based on GuruFocus' analysis, Gubra AS (FRA:PI3) is currently considered Significantly Overvalued. The stock's GF Value™ is €26.59, compared to a current price of €41.06 — trading 54.4% above its estimated fair value. The current Cash Flow from Others is €-59.59 Mil. Gubra AS's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Others calculated?
Cash Flow from Others is calculated from a company's financial statements. For Gubra AS (FRA:PI3), the current Cash Flow from Others is €-59.59 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gubra AS (FRA:PI3) Overvalued in 2026?

Based on GuruFocus' analysis, Gubra AS stock appears to be overvalued. The current stock price of €41.06 is trading 54.4% above its estimated GF Value™ of €26.59. GuruFocus considers Gubra AS to be Significantly Overvalued.

Key valuation signals for FRA:PI3:

  • Cash Flow from Others: €-59.59 Mil
  • GF Value™: €26.59 vs. price of €41.06 (54.4% above fair value)
  • GF Score™: 76/100 with 4 warning signs

No single metric tells the full story. See the FRA:PI3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gubra AS Business Description

Other Exchanges GUBRA:DenmarkPI3:Germany
Address Horsholm Kongevej 11B, Horsholm, DNK, 2970
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has two segments: Pre-clinical contract research (CRO), which derives maximum revenue and Biotech Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
76GF Score

Get the complete analysis for FRA:PI3

Cash Flow from Others is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€41.06
Price
€26.59
GF Value